Close
Nordic 9Nordic 9

AdBio partners (investor - Venture Capital)

France adbio.partners
See something wrong or missing? Let us know
Offices:Paris

AdBio partners is a venture capital fund supported in particular by the National Seed-Fund from France, with a focus on early-stage startups in life sciences in Europe.

Average round investment:29.87M USD
Average number per year:2.4
Distribution: 2025 (5)2024 (2)2023 (6)2022 (1)2021 (1) See the entire list
Portfolio companies: Spain Arthex Biotech S.L.Spain Integra TxSwitzerland EvlaBio See the entire list
Mostly invests in: Belgium Belgium (6) Biotech (17)
See the entire list

Showing 3 of 17 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

AdBio partners mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to AdBio partners

Name Criteria
Italy Angelini Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, France, Switzerland, Denmark
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Ireland Seroba Life Sciences
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: France
  • Average number of deals per year: 2.6
  • Active last 12 months: Yes
Germany Boehringer Ingelheim Venture Fund
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, France, Switzerland
  • Average number of deals per year: 4.0
  • Active last 12 months: Yes
Spain Kibo Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Spain
  • Average number of deals per year: 4.0
  • Active last 12 months: Yes
United Kingdom Eli Lilly and Company
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, France, Switzerland, Denmark
  • Average number of deals per year: 4.0
  • Active last 12 months: Yes
Germany Bosch Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium, France, Spain, Switzerland
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
United States Pfizer Venture Investments
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, Switzerland
  • Average number of deals per year: 2.6
  • Active last 12 months: Yes
United States Adjuvant Capital
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, Switzerland, Denmark
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Netherlands Icos Capital Management
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: France, Spain
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Belgium V-Bio Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: Belgium, France, Denmark
  • Average number of deals per year: 2.7
  • Active last 12 months: Yes
Top